APO Research
Talk to an analyst

APO RESEARCH · REPORT

FIC Dual-target Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global FIC Dual-target Drugs Market Analysis and Forecast 2026-2032

29 December 2025201 pages

Choose your research edition.

Industry ResearchFIC Dual-target Drugs Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal FIC Dual-target Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal FIC Dual-target Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal FIC Dual-target Drugs Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal FIC Dual-target Drugs Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

The global FIC Dual-target Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for FIC Dual-target Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for FIC Dual-target Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for FIC Dual-target Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for FIC Dual-target Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of FIC Dual-target Drugs include Agios, BMS, Boehringer Ingelheim, Dermavant Sciences, Genentech, Gilead, Immunocore, ImmunoGen and Mallinckrodt, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for FIC Dual-target Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of FIC Dual-target Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for FIC Dual-target Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the FIC Dual-target Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global FIC Dual-target Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for FIC Dual-target Drugs sales, projected growth trends, production technology, application and end-user industry.

FIC Dual-target Drugs Segment by Company

Agios

BMS

Boehringer Ingelheim

Dermavant Sciences

Genentech

Gilead

Immunocore

ImmunoGen

Mallinckrodt

Marinus

Phathom

Polarean lmaging

Pfizer

Eli Lilly

Roche

Merck

Novartis

Johnson & Johnson

Sanofi

FIC Dual-target Drugs Segment by Type

Polθ/PARP Targets

GPX4/CDK Targets

EZH2/HSP90 Targets

Others

FIC Dual-target Drugs Segment by Application

Hospital

Clinic

Other

FIC Dual-target Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FIC Dual-target Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of FIC Dual-target Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FIC Dual-target Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of FIC Dual-target Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of FIC Dual-target Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, FIC Dual-target Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global FIC Dual-target Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Polθ/PARP Targets Major Manufacturers Table 3. GPX4/CDK Targets Major Manufacturers Table 4. EZH2/HSP90 Targets Major Manufacturers Table 5. Others Major Manufacturers Table 6. Global FIC Dual-target Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Manufacturers Table 8. Clinic Major Manufacturers Table 9. Other Major Manufacturers Table 10. FIC Dual-target Drugs Industry Trends Table 11. FIC Dual-target Drugs Industry Drivers Table 12. FIC Dual-target Drugs Industry Opportunities and Challenges Table 13. FIC Dual-target Drugs Industry Restraints Table 14. Global FIC Dual-target Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global FIC Dual-target Drugs Revenue by Region (2021-2026) & (US$ Million) Table 16. Global FIC Dual-target Drugs Revenue by Region (2027-2032) & (US$ Million) Table 17. Global FIC Dual-target Drugs Revenue Market Share by Region (2021-2026) Table 18. Global FIC Dual-target Drugs Revenue Market Share by Region (2027-2032) Table 19. Global FIC Dual-target Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global FIC Dual-target Drugs Sales by Region (2021-2026) & (K Units) Table 21. Global FIC Dual-target Drugs Sales by Region (2027-2032) & (K Units) Table 22. Global FIC Dual-target Drugs Sales Market Share by Region (2021-2026) Table 23. Global FIC Dual-target Drugs Sales Market Share by Region (2027-2032) Table 24. Global FIC Dual-target Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global FIC Dual-target Drugs Revenue Market Share by Manufacturers (2021-2026) Table 26. Global FIC Dual-target Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global FIC Dual-target Drugs Sales Market Share by Manufacturers (2021-2026) Table 28. Global FIC Dual-target Drugs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global FIC Dual-target Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global FIC Dual-target Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global FIC Dual-target Drugs Manufacturers, Product Type & Application Table 32. Global FIC Dual-target Drugs Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global FIC Dual-target Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global FIC Dual-target Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global FIC Dual-target Drugs Revenue by Type (2021-2026) & (US$ Million) Table 37. Global FIC Dual-target Drugs Revenue by Type (2027-2032) & (US$ Million) Table 38. Global FIC Dual-target Drugs Revenue Market Share by Type (2021-2026) Table 39. Global FIC Dual-target Drugs Revenue Market Share by Type (2027-2032) Table 40. Global FIC Dual-target Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global FIC Dual-target Drugs Sales by Type (2021-2026) & (K Units) Table 42. Global FIC Dual-target Drugs Sales by Type (2027-2032) & (K Units) Table 43. Global FIC Dual-target Drugs Sales Market Share by Type (2021-2026) Table 44. Global FIC Dual-target Drugs Sales Market Share by Type (2027-2032) Table 45. Global FIC Dual-target Drugs Price by Type (2021-2026) & (US$/Unit) Table 46. Global FIC Dual-target Drugs Price by Type (2027-2032) & (US$/Unit) Table 47. Global FIC Dual-target Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global FIC Dual-target Drugs Revenue by Application (2021-2026) & (US$ Million) Table 49. Global FIC Dual-target Drugs Revenue by Application (2027-2032) & (US$ Million) Table 50. Global FIC Dual-target Drugs Revenue Market Share by Application (2021-2026) Table 51. Global FIC Dual-target Drugs Revenue Market Share by Application (2027-2032) Table 52. Global FIC Dual-target Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global FIC Dual-target Drugs Sales by Application (2021-2026) & (K Units) Table 54. Global FIC Dual-target Drugs Sales by Application (2027-2032) & (K Units) Table 55. Global FIC Dual-target Drugs Sales Market Share by Application (2021-2026) Table 56. Global FIC Dual-target Drugs Sales Market Share by Application (2027-2032) Table 57. Global FIC Dual-target Drugs Price by Application (2021-2026) & (US$/Unit) Table 58. Global FIC Dual-target Drugs Price by Application (2027-2032) & (US$/Unit) Table 59. Agios Company Information Table 60. Agios Business Overview Table 61. Agios FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Agios FIC Dual-target Drugs Product Portfolio Table 63. Agios Recent Development Table 64. BMS Company Information Table 65. BMS Business Overview Table 66. BMS FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. BMS FIC Dual-target Drugs Product Portfolio Table 68. BMS Recent Development Table 69. Boehringer Ingelheim Company Information Table 70. Boehringer Ingelheim Business Overview Table 71. Boehringer Ingelheim FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Boehringer Ingelheim FIC Dual-target Drugs Product Portfolio Table 73. Boehringer Ingelheim Recent Development Table 74. Dermavant Sciences Company Information Table 75. Dermavant Sciences Business Overview Table 76. Dermavant Sciences FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Dermavant Sciences FIC Dual-target Drugs Product Portfolio Table 78. Dermavant Sciences Recent Development Table 79. Genentech Company Information Table 80. Genentech Business Overview Table 81. Genentech FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Genentech FIC Dual-target Drugs Product Portfolio Table 83. Genentech Recent Development Table 84. Gilead Company Information Table 85. Gilead Business Overview Table 86. Gilead FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Gilead FIC Dual-target Drugs Product Portfolio Table 88. Gilead Recent Development Table 89. Immunocore Company Information Table 90. Immunocore Business Overview Table 91. Immunocore FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Immunocore FIC Dual-target Drugs Product Portfolio Table 93. Immunocore Recent Development Table 94. ImmunoGen Company Information Table 95. ImmunoGen Business Overview Table 96. ImmunoGen FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. ImmunoGen FIC Dual-target Drugs Product Portfolio Table 98. ImmunoGen Recent Development Table 99. Mallinckrodt Company Information Table 100. Mallinckrodt Business Overview Table 101. Mallinckrodt FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Mallinckrodt FIC Dual-target Drugs Product Portfolio Table 103. Mallinckrodt Recent Development Table 104. Marinus Company Information Table 105. Marinus Business Overview Table 106. Marinus FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Marinus FIC Dual-target Drugs Product Portfolio Table 108. Marinus Recent Development Table 109. Phathom Company Information Table 110. Phathom Business Overview Table 111. Phathom FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Phathom FIC Dual-target Drugs Product Portfolio Table 113. Phathom Recent Development Table 114. Polarean lmaging Company Information Table 115. Polarean lmaging Business Overview Table 116. Polarean lmaging FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Polarean lmaging FIC Dual-target Drugs Product Portfolio Table 118. Polarean lmaging Recent Development Table 119. Pfizer Company Information Table 120. Pfizer Business Overview Table 121. Pfizer FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Pfizer FIC Dual-target Drugs Product Portfolio Table 123. Pfizer Recent Development Table 124. Eli Lilly Company Information Table 125. Eli Lilly Business Overview Table 126. Eli Lilly FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Eli Lilly FIC Dual-target Drugs Product Portfolio Table 128. Eli Lilly Recent Development Table 129. Roche Company Information Table 130. Roche Business Overview Table 131. Roche FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Roche FIC Dual-target Drugs Product Portfolio Table 133. Roche Recent Development Table 134. Merck Company Information Table 135. Merck Business Overview Table 136. Merck FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Merck FIC Dual-target Drugs Product Portfolio Table 138. Merck Recent Development Table 139. Novartis Company Information Table 140. Novartis Business Overview Table 141. Novartis FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Novartis FIC Dual-target Drugs Product Portfolio Table 143. Novartis Recent Development Table 144. Johnson & Johnson Company Information Table 145. Johnson & Johnson Business Overview Table 146. Johnson & Johnson FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Johnson & Johnson FIC Dual-target Drugs Product Portfolio Table 148. Johnson & Johnson Recent Development Table 149. Sanofi Company Information Table 150. Sanofi Business Overview Table 151. Sanofi FIC Dual-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Sanofi FIC Dual-target Drugs Product Portfolio Table 153. Sanofi Recent Development Table 154. North America FIC Dual-target Drugs Revenue by Type (2021-2026) & (US$ Million) Table 155. North America FIC Dual-target Drugs Revenue by Type (2027-2032) & (US$ Million) Table 156. North America FIC Dual-target Drugs Sales by Type (2021-2026) & (K Units) Table 157. North America FIC Dual-target Drugs Sales by Type (2027-2032) & (K Units) Table 158. North America FIC Dual-target Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 159. North America FIC Dual-target Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 160. North America FIC Dual-target Drugs Revenue by Application (2021-2026) & (US$ Million) Table 161. North America FIC Dual-target Drugs Revenue by Application (2027-2032) & (US$ Million) Table 162. North America FIC Dual-target Drugs Sales by Application (2021-2026) & (K Units) Table 163. North America FIC Dual-target Drugs Sales by Application (2027-2032) & (K Units) Table 164. North America FIC Dual-target Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 165. North America FIC Dual-target Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 166. North America FIC Dual-target Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 167. North America FIC Dual-target Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 168. North America FIC Dual-target Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 169. North America FIC Dual-target Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 170. North America FIC Dual-target Drugs Sales by Country (2021-2026) & (K Units) Table 171. North America FIC Dual-target Drugs Sales by Country (2027-2032) & (K Units) Table 172. North America FIC Dual-target Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 173. North America FIC Dual-target Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 174. United States FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 175. Canada FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 176. Mexico FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 177. Europe FIC Dual-target Drugs Revenue by Type (2021-2026) & (US$ Million) Table 178. Europe FIC Dual-target Drugs Revenue by Type (2027-2032) & (US$ Million) Table 179. Europe FIC Dual-target Drugs Sales by Type (2021-2026) & (K Units) Table 180. Europe FIC Dual-target Drugs Sales by Type (2027-2032) & (K Units) Table 181. Europe FIC Dual-target Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 182. Europe FIC Dual-target Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 183. Europe FIC Dual-target Drugs Revenue by Application (2021-2026) & (US$ Million) Table 184. Europe FIC Dual-target Drugs Revenue by Application (2027-2032) & (US$ Million) Table 185. Europe FIC Dual-target Drugs Sales by Application (2021-2026) & (K Units) Table 186. Europe FIC Dual-target Drugs Sales by Application (2027-2032) & (K Units) Table 187. Europe FIC Dual-target Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 188. Europe FIC Dual-target Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 189. Europe FIC Dual-target Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 190. Europe FIC Dual-target Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 191. Europe FIC Dual-target Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 192. Europe FIC Dual-target Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 193. Europe FIC Dual-target Drugs Sales by Country (2021-2026) & (K Units) Table 194. Europe FIC Dual-target Drugs Sales by Country (2027-2032) & (K Units) Table 195. Europe FIC Dual-target Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 196. Europe FIC Dual-target Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 197. Germany FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 198. France FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 199. U.K. FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 200. Italy FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 201. Russia FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 202. Spain FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 203. Netherlands FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 204. Switzerland FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 205. Sweden FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 206. Poland FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 207. China FIC Dual-target Drugs Revenue by Type (2021-2026) & (US$ Million) Table 208. China FIC Dual-target Drugs Revenue by Type (2027-2032) & (US$ Million) Table 209. China FIC Dual-target Drugs Sales by Type (2021-2026) & (K Units) Table 210. China FIC Dual-target Drugs Sales by Type (2027-2032) & (K Units) Table 211. China FIC Dual-target Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 212. China FIC Dual-target Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 213. China FIC Dual-target Drugs Revenue by Application (2021-2026) & (US$ Million) Table 214. China FIC Dual-target Drugs Revenue by Application (2027-2032) & (US$ Million) Table 215. China FIC Dual-target Drugs Sales by Application (2021-2026) & (K Units) Table 216. China FIC Dual-target Drugs Sales by Application (2027-2032) & (K Units) Table 217. China FIC Dual-target Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 218. China FIC Dual-target Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 219. Asia FIC Dual-target Drugs Revenue by Type (2021-2026) & (US$ Million) Table 220. Asia FIC Dual-target Drugs Revenue by Type (2027-2032) & (US$ Million) Table 221. Asia FIC Dual-target Drugs Sales by Type (2021-2026) & (K Units) Table 222. Asia FIC Dual-target Drugs Sales by Type (2027-2032) & (K Units) Table 223. Asia FIC Dual-target Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 224. Asia FIC Dual-target Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 225. Asia FIC Dual-target Drugs Revenue by Application (2021-2026) & (US$ Million) Table 226. Asia FIC Dual-target Drugs Revenue by Application (2027-2032) & (US$ Million) Table 227. Asia FIC Dual-target Drugs Sales by Application (2021-2026) & (K Units) Table 228. Asia FIC Dual-target Drugs Sales by Application (2027-2032) & (K Units) Table 229. Asia FIC Dual-target Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 230. Asia FIC Dual-target Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 231. Asia FIC Dual-target Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 232. Asia FIC Dual-target Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 233. Asia FIC Dual-target Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 234. Asia FIC Dual-target Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 235. Asia FIC Dual-target Drugs Sales by Country (2021-2026) & (K Units) Table 236. Asia FIC Dual-target Drugs Sales by Country (2027-2032) & (K Units) Table 237. Asia FIC Dual-target Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 238. Asia FIC Dual-target Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 239. Japan FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 240. South Korea FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 241. India FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 242. Australia FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 243. Taiwan FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 244. Southeast Asia FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 245. SAMEA FIC Dual-target Drugs Revenue by Type (2021-2026) & (US$ Million) Table 246. SAMEA FIC Dual-target Drugs Revenue by Type (2027-2032) & (US$ Million) Table 247. SAMEA FIC Dual-target Drugs Sales by Type (2021-2026) & (K Units) Table 248. SAMEA FIC Dual-target Drugs Sales by Type (2027-2032) & (K Units) Table 249. SAMEA FIC Dual-target Drugs Sales Price by Type (2021-2026) & (US$/Unit) Table 250. SAMEA FIC Dual-target Drugs Sales Price by Type (2027-2032) & (US$/Unit) Table 251. SAMEA FIC Dual-target Drugs Revenue by Application (2021-2026) & (US$ Million) Table 252. SAMEA FIC Dual-target Drugs Revenue by Application (2027-2032) & (US$ Million) Table 253. SAMEA FIC Dual-target Drugs Sales by Application (2021-2026) & (K Units) Table 254. SAMEA FIC Dual-target Drugs Sales by Application (2027-2032) & (K Units) Table 255. SAMEA FIC Dual-target Drugs Sales Price by Application (2021-2026) & (US$/Unit) Table 256. SAMEA FIC Dual-target Drugs Sales Price by Application (2027-2032) & (US$/Unit) Table 257. SAMEA FIC Dual-target Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 258. SAMEA FIC Dual-target Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 259. SAMEA FIC Dual-target Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 260. SAMEA FIC Dual-target Drugs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 261. SAMEA FIC Dual-target Drugs Sales by Country (2021-2026) & (K Units) Table 262. SAMEA FIC Dual-target Drugs Sales by Country (2027-2032) & (K Units) Table 263. SAMEA FIC Dual-target Drugs Sales Price by Country (2021-2026) & (US$/Unit) Table 264. SAMEA FIC Dual-target Drugs Sales Price by Country (2027-2032) & (US$/Unit) Table 265. Brazil FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 266. Argentina FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 267. Chile FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 268. Colombia FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 269. Peru FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 270. Saudi Arabia FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 271. Israel FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 272. UAE FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 273. Turkey FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 274. Iran FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 275. Egypt FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Table 276. Key Raw Materials Table 277. Raw Materials Key Suppliers Table 278. FIC Dual-target Drugs Distributors List Table 279. FIC Dual-target Drugs Customers List Table 280. Research Programs/Design for This Report Table 281. Authors List of This Report Table 282. Secondary Sources Table 283. Primary Sources List of Figures Figure 1. FIC Dual-target Drugs Image Figure 2. Global FIC Dual-target Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global FIC Dual-target Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Polθ/PARP Targets Image Figure 5. GPX4/CDK Targets Image Figure 6. EZH2/HSP90 Targets Image Figure 7. Others Image Figure 8. Global FIC Dual-target Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global FIC Dual-target Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Clinic Image Figure 12. Other Image Figure 13. Global FIC Dual-target Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global FIC Dual-target Drugs Revenue (2021-2032) & (US$ Million) Figure 15. Global FIC Dual-target Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global FIC Dual-target Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global FIC Dual-target Drugs Revenue Market Share by Region (2021-2032) Figure 18. Global FIC Dual-target Drugs Sales (2021-2032) & (K Units) Figure 19. Global FIC Dual-target Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global FIC Dual-target Drugs Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico FIC Dual-target Drugs Sales YoY (2021-2032) & (K Units) Figure 22. Europe FIC Dual-target Drugs Sales YoY (2021-2032) & (K Units) Figure 23. China FIC Dual-target Drugs Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) FIC Dual-target Drugs Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa FIC Dual-target Drugs Sales YoY (2021-2032) & (K Units) Figure 26. Global FIC Dual-target Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global FIC Dual-target Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global FIC Dual-target Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global FIC Dual-target Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global FIC Dual-target Drugs Revenue Market Share by Type (2021-2032) Figure 32. Global FIC Dual-target Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global FIC Dual-target Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global FIC Dual-target Drugs Sales Market Share by Type (2021-2032) Figure 35. Global FIC Dual-target Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global FIC Dual-target Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global FIC Dual-target Drugs Revenue Market Share by Application (2021-2032) Figure 38. Global FIC Dual-target Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global FIC Dual-target Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global FIC Dual-target Drugs Sales Market Share by Application (2021-2032) Figure 41. North America FIC Dual-target Drugs Revenue Share by Type (2021-2032) Figure 42. North America FIC Dual-target Drugs Sales Share by Type (2021-2032) Figure 43. North America FIC Dual-target Drugs Revenue Share by Application (2021-2032) Figure 44. North America FIC Dual-target Drugs Sales Share by Application (2021-2032) Figure 45. North America FIC Dual-target Drugs Revenue Share by Country (2021-2032) Figure 46. North America FIC Dual-target Drugs Sales Share by Country (2021-2032) Figure 47. Europe FIC Dual-target Drugs Revenue Share by Type (2021-2032) Figure 48. Europe FIC Dual-target Drugs Sales Share by Type (2021-2032) Figure 49. Europe FIC Dual-target Drugs Revenue Share by Application (2021-2032) Figure 50. Europe FIC Dual-target Drugs Sales Share by Application (2021-2032) Figure 51. Europe FIC Dual-target Drugs Revenue Share by Country (2021-2032) Figure 52. Europe FIC Dual-target Drugs Sales Share by Country (2021-2032) Figure 53. China FIC Dual-target Drugs Revenue Share by Type (2021-2032) Figure 54. China FIC Dual-target Drugs Sales Share by Type (2021-2032) Figure 55. China FIC Dual-target Drugs Revenue Share by Application (2021-2032) Figure 56. China FIC Dual-target Drugs Sales Share by Application (2021-2032) Figure 57. Asia FIC Dual-target Drugs Revenue Share by Type (2021-2032) Figure 58. Asia FIC Dual-target Drugs Sales Share by Type (2021-2032) Figure 59. Asia FIC Dual-target Drugs Revenue Share by Application (2021-2032) Figure 60. Asia FIC Dual-target Drugs Sales Share by Application (2021-2032) Figure 61. Asia FIC Dual-target Drugs Revenue Share by Country (2021-2032) Figure 62. Asia FIC Dual-target Drugs Sales Share by Country (2021-2032) Figure 63. SAMEA FIC Dual-target Drugs Revenue Share by Type (2021-2032) Figure 64. SAMEA FIC Dual-target Drugs Sales Share by Type (2021-2032) Figure 65. SAMEA FIC Dual-target Drugs Revenue Share by Application (2021-2032) Figure 66. SAMEA FIC Dual-target Drugs Sales Share by Application (2021-2032) Figure 67. SAMEA FIC Dual-target Drugs Revenue Share by Country (2021-2032) Figure 68. SAMEA FIC Dual-target Drugs Sales Share by Country (2021-2032) Figure 69. FIC Dual-target Drugs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. FIC Dual-target Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Polθ/PARP Targets
  • GPX4/CDK Targets
  • EZH2/HSP90 Targets
  • Others
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Agios
  • BMS
  • Boehringer Ingelheim
  • Dermavant Sciences
  • Genentech
  • Gilead
  • Immunocore
  • ImmunoGen
  • Mallinckrodt
  • Marinus
  • Phathom
  • Polarean lmaging
  • Pfizer
  • Eli Lilly
  • Roche
  • Merck
  • Novartis
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 FIC Dual-target Drugs Market by Type
  3. 1.2.1 Global FIC Dual-target Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Polθ/PARP Targets
  5. 1.2.3 GPX4/CDK Targets
  6. 1.2.4 EZH2/HSP90 Targets
  7. 1.2.5 Others
  8. 1.3 FIC Dual-target Drugs Market by Application
  9. 1.3.1 Global FIC Dual-target Drugs Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Clinic
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 FIC Dual-target Drugs Market Dynamics
  1. 2.1 FIC Dual-target Drugs Industry Trends
  2. 2.2 FIC Dual-target Drugs Industry Drivers
  3. 2.3 FIC Dual-target Drugs Industry Opportunities and Challenges
  4. 2.4 FIC Dual-target Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global FIC Dual-target Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global FIC Dual-target Drugs Revenue by Region
  3. 3.2.1 Global FIC Dual-target Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global FIC Dual-target Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global FIC Dual-target Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global FIC Dual-target Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global FIC Dual-target Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global FIC Dual-target Drugs Sales by Region
  9. 3.4.1 Global FIC Dual-target Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global FIC Dual-target Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global FIC Dual-target Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global FIC Dual-target Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global FIC Dual-target Drugs Revenue by Manufacturers
  2. 4.1.1 Global FIC Dual-target Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global FIC Dual-target Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global FIC Dual-target Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global FIC Dual-target Drugs Sales by Manufacturers
  6. 4.2.1 Global FIC Dual-target Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global FIC Dual-target Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global FIC Dual-target Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global FIC Dual-target Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global FIC Dual-target Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global FIC Dual-target Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global FIC Dual-target Drugs Manufacturers, Product Type & Application
  13. 4.7 Global FIC Dual-target Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global FIC Dual-target Drugs Market CR5 and HHI
  16. 4.8.2 2025 FIC Dual-target Drugs Tier 1, Tier 2, and Tier 3
5 FIC Dual-target Drugs Market by Type
  1. 5.1 Global FIC Dual-target Drugs Revenue by Type
  2. 5.1.1 Global FIC Dual-target Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global FIC Dual-target Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global FIC Dual-target Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global FIC Dual-target Drugs Sales by Type
  6. 5.2.1 Global FIC Dual-target Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global FIC Dual-target Drugs Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global FIC Dual-target Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global FIC Dual-target Drugs Price by Type
6 FIC Dual-target Drugs Market by Application
  1. 6.1 Global FIC Dual-target Drugs Revenue by Application
  2. 6.1.1 Global FIC Dual-target Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global FIC Dual-target Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global FIC Dual-target Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global FIC Dual-target Drugs Sales by Application
  6. 6.2.1 Global FIC Dual-target Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global FIC Dual-target Drugs Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global FIC Dual-target Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global FIC Dual-target Drugs Price by Application
7 Company Profiles
  1. 7.1 Agios
  2. 7.1.1 Agios Company Information
  3. 7.1.2 Agios Business Overview
  4. 7.1.3 Agios FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Agios FIC Dual-target Drugs Product Portfolio
  6. 7.1.5 Agios Recent Developments
  7. 7.2 BMS
  8. 7.2.1 BMS Company Information
  9. 7.2.2 BMS Business Overview
  10. 7.2.3 BMS FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 BMS FIC Dual-target Drugs Product Portfolio
  12. 7.2.5 BMS Recent Developments
  13. 7.3 Boehringer Ingelheim
  14. 7.3.1 Boehringer Ingelheim Company Information
  15. 7.3.2 Boehringer Ingelheim Business Overview
  16. 7.3.3 Boehringer Ingelheim FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Boehringer Ingelheim FIC Dual-target Drugs Product Portfolio
  18. 7.3.5 Boehringer Ingelheim Recent Developments
  19. 7.4 Dermavant Sciences
  20. 7.4.1 Dermavant Sciences Company Information
  21. 7.4.2 Dermavant Sciences Business Overview
  22. 7.4.3 Dermavant Sciences FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Dermavant Sciences FIC Dual-target Drugs Product Portfolio
  24. 7.4.5 Dermavant Sciences Recent Developments
  25. 7.5 Genentech
  26. 7.5.1 Genentech Company Information
  27. 7.5.2 Genentech Business Overview
  28. 7.5.3 Genentech FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Genentech FIC Dual-target Drugs Product Portfolio
  30. 7.5.5 Genentech Recent Developments
  31. 7.6 Gilead
  32. 7.6.1 Gilead Company Information
  33. 7.6.2 Gilead Business Overview
  34. 7.6.3 Gilead FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Gilead FIC Dual-target Drugs Product Portfolio
  36. 7.6.5 Gilead Recent Developments
  37. 7.7 Immunocore
  38. 7.7.1 Immunocore Company Information
  39. 7.7.2 Immunocore Business Overview
  40. 7.7.3 Immunocore FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Immunocore FIC Dual-target Drugs Product Portfolio
  42. 7.7.5 Immunocore Recent Developments
  43. 7.8 ImmunoGen
  44. 7.8.1 ImmunoGen Company Information
  45. 7.8.2 ImmunoGen Business Overview
  46. 7.8.3 ImmunoGen FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 ImmunoGen FIC Dual-target Drugs Product Portfolio
  48. 7.8.5 ImmunoGen Recent Developments
  49. 7.9 Mallinckrodt
  50. 7.9.1 Mallinckrodt Company Information
  51. 7.9.2 Mallinckrodt Business Overview
  52. 7.9.3 Mallinckrodt FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Mallinckrodt FIC Dual-target Drugs Product Portfolio
  54. 7.9.5 Mallinckrodt Recent Developments
  55. 7.10 Marinus
  56. 7.10.1 Marinus Company Information
  57. 7.10.2 Marinus Business Overview
  58. 7.10.3 Marinus FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Marinus FIC Dual-target Drugs Product Portfolio
  60. 7.10.5 Marinus Recent Developments
  61. 7.11 Phathom
  62. 7.11.1 Phathom Company Information
  63. 7.11.2 Phathom Business Overview
  64. 7.11.3 Phathom FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Phathom FIC Dual-target Drugs Product Portfolio
  66. 7.11.5 Phathom Recent Developments
  67. 7.12 Polarean lmaging
  68. 7.12.1 Polarean lmaging Company Information
  69. 7.12.2 Polarean lmaging Business Overview
  70. 7.12.3 Polarean lmaging FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Polarean lmaging FIC Dual-target Drugs Product Portfolio
  72. 7.12.5 Polarean lmaging Recent Developments
  73. 7.13 Pfizer
  74. 7.13.1 Pfizer Company Information
  75. 7.13.2 Pfizer Business Overview
  76. 7.13.3 Pfizer FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Pfizer FIC Dual-target Drugs Product Portfolio
  78. 7.13.5 Pfizer Recent Developments
  79. 7.14 Eli Lilly
  80. 7.14.1 Eli Lilly Company Information
  81. 7.14.2 Eli Lilly Business Overview
  82. 7.14.3 Eli Lilly FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Eli Lilly FIC Dual-target Drugs Product Portfolio
  84. 7.14.5 Eli Lilly Recent Developments
  85. 7.15 Roche
  86. 7.15.1 Roche Company Information
  87. 7.15.2 Roche Business Overview
  88. 7.15.3 Roche FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Roche FIC Dual-target Drugs Product Portfolio
  90. 7.15.5 Roche Recent Developments
  91. 7.16 Merck
  92. 7.16.1 Merck Company Information
  93. 7.16.2 Merck Business Overview
  94. 7.16.3 Merck FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Merck FIC Dual-target Drugs Product Portfolio
  96. 7.16.5 Merck Recent Developments
  97. 7.17 Novartis
  98. 7.17.1 Novartis Company Information
  99. 7.17.2 Novartis Business Overview
  100. 7.17.3 Novartis FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Novartis FIC Dual-target Drugs Product Portfolio
  102. 7.17.5 Novartis Recent Developments
  103. 7.18 Johnson & Johnson
  104. 7.18.1 Johnson & Johnson Company Information
  105. 7.18.2 Johnson & Johnson Business Overview
  106. 7.18.3 Johnson & Johnson FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Johnson & Johnson FIC Dual-target Drugs Product Portfolio
  108. 7.18.5 Johnson & Johnson Recent Developments
  109. 7.19 Sanofi
  110. 7.19.1 Sanofi Company Information
  111. 7.19.2 Sanofi Business Overview
  112. 7.19.3 Sanofi FIC Dual-target Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Sanofi FIC Dual-target Drugs Product Portfolio
  114. 7.19.5 Sanofi Recent Developments
8 North America
  1. 8.1 North America FIC Dual-target Drugs Market Size by Type
  2. 8.1.1 North America FIC Dual-target Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America FIC Dual-target Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America FIC Dual-target Drugs Price by Type (2021-2032)
  5. 8.2 North America FIC Dual-target Drugs Market Size by Application
  6. 8.2.1 North America FIC Dual-target Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America FIC Dual-target Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America FIC Dual-target Drugs Price by Application (2021-2032)
  9. 8.3 North America FIC Dual-target Drugs Market Size by Country
  10. 8.3.1 North America FIC Dual-target Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America FIC Dual-target Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America FIC Dual-target Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe FIC Dual-target Drugs Market Size by Type
  2. 9.1.1 Europe FIC Dual-target Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe FIC Dual-target Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe FIC Dual-target Drugs Price by Type (2021-2032)
  5. 9.2 Europe FIC Dual-target Drugs Market Size by Application
  6. 9.2.1 Europe FIC Dual-target Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe FIC Dual-target Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe FIC Dual-target Drugs Price by Application (2021-2032)
  9. 9.3 Europe FIC Dual-target Drugs Market Size by Country
  10. 9.3.1 Europe FIC Dual-target Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe FIC Dual-target Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe FIC Dual-target Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China FIC Dual-target Drugs Market Size by Type
  2. 10.1.1 China FIC Dual-target Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China FIC Dual-target Drugs Sales by Type (2021-2032)
  4. 10.1.3 China FIC Dual-target Drugs Price by Type (2021-2032)
  5. 10.2 China FIC Dual-target Drugs Market Size by Application
  6. 10.2.1 China FIC Dual-target Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China FIC Dual-target Drugs Sales by Application (2021-2032)
  8. 10.2.3 China FIC Dual-target Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia FIC Dual-target Drugs Market Size by Type
  2. 11.1.1 Asia FIC Dual-target Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia FIC Dual-target Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia FIC Dual-target Drugs Price by Type (2021-2032)
  5. 11.2 Asia FIC Dual-target Drugs Market Size by Application
  6. 11.2.1 Asia FIC Dual-target Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia FIC Dual-target Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia FIC Dual-target Drugs Price by Application (2021-2032)
  9. 11.3 Asia FIC Dual-target Drugs Market Size by Country
  10. 11.3.1 Asia FIC Dual-target Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia FIC Dual-target Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia FIC Dual-target Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA FIC Dual-target Drugs Market Size by Type
  2. 12.1.1 SAMEA FIC Dual-target Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA FIC Dual-target Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA FIC Dual-target Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA FIC Dual-target Drugs Market Size by Application
  6. 12.2.1 SAMEA FIC Dual-target Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA FIC Dual-target Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA FIC Dual-target Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA FIC Dual-target Drugs Market Size by Country
  10. 12.3.1 SAMEA FIC Dual-target Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA FIC Dual-target Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA FIC Dual-target Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 FIC Dual-target Drugs Value Chain Analysis
  2. 13.1.1 FIC Dual-target Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 FIC Dual-target Drugs Production Mode & Process
  6. 13.2 FIC Dual-target Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 FIC Dual-target Drugs Distributors
  9. 13.2.3 FIC Dual-target Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst